MA54695A - Inhibiteurs de dihydroorotate déshydrogénase - Google Patents

Inhibiteurs de dihydroorotate déshydrogénase

Info

Publication number
MA54695A
MA54695A MA054695A MA54695A MA54695A MA 54695 A MA54695 A MA 54695A MA 054695 A MA054695 A MA 054695A MA 54695 A MA54695 A MA 54695A MA 54695 A MA54695 A MA 54695A
Authority
MA
Morocco
Prior art keywords
dehydrogenase inhibitors
dihydroorotate dehydrogenase
dihydroorotate
inhibitors
dehydrogenase
Prior art date
Application number
MA054695A
Other languages
English (en)
Inventor
Justin Cisar
Edgar Jacoby
Colleen Elizabeth Keohane
Scott Kuduk
Yvan Rene Ferdinand Simonnet
Chao-Yuan Wang
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA54695A publication Critical patent/MA54695A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA054695A 2019-01-11 2020-01-10 Inhibiteurs de dihydroorotate déshydrogénase MA54695A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962791057P 2019-01-11 2019-01-11
US201962859851P 2019-06-11 2019-06-11

Publications (1)

Publication Number Publication Date
MA54695A true MA54695A (fr) 2021-11-17

Family

ID=69326572

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054695A MA54695A (fr) 2019-01-11 2020-01-10 Inhibiteurs de dihydroorotate déshydrogénase

Country Status (16)

Country Link
US (1) US20220089568A1 (fr)
EP (1) EP3908579B1 (fr)
JP (1) JP2022517086A (fr)
KR (1) KR20210114968A (fr)
CN (1) CN113574054A (fr)
AU (1) AU2020205842A1 (fr)
BR (1) BR112021013134A2 (fr)
CA (1) CA3126330A1 (fr)
ES (1) ES2971680T3 (fr)
IL (1) IL284537A (fr)
MA (1) MA54695A (fr)
MX (1) MX2021008400A (fr)
PH (1) PH12021551626A1 (fr)
SG (1) SG11202107276WA (fr)
TW (1) TW202043208A (fr)
WO (1) WO2020144638A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
CA3159578A1 (fr) * 2019-11-01 2021-05-06 Janssen Biotech, Inc. Derives de quinoleine et de quinoxaline fluores utilises en tant qu'inhibiteurs de dihydroorotate deshydrogenase (dhodh) pour le traitement du cancer, de maladies auto-immunes et inflammatoires
EP4185577A4 (fr) * 2020-07-14 2024-08-07 Nanjing Zenshine Pharmaceuticals Co., Ltd. Composés en tant qu'inhibiteurs de dhodh
WO2022063299A1 (fr) * 2020-09-28 2022-03-31 微境生物医药科技(上海)有限公司 Dérivé de 1,2,4-triazolone servant d'inhibiteur de dhodh
WO2022070069A1 (fr) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Inhibiteurs de la dihydroorotate déshydrogénase
WO2022074534A1 (fr) 2020-10-05 2022-04-14 Janssen Biotech, Inc. Combinaisons d'inhibiteurs de dihydroorotate déshydrogénase et d'agents hypométhylants
EP4313150A1 (fr) 2021-03-26 2024-02-07 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Combinaison d'inhibiteur de la biosynthèse de la pyrimidine destinée à être utilisée dans le traitement d'infections virales
US12577250B2 (en) 2021-07-05 2026-03-17 Wigen Biomedicine Technology (shanghai) Co., Ltd. 1,2,4-triazolone derivative as DHODH inhibitor, and preparation method therefor and use thereof
WO2025034810A1 (fr) * 2023-08-08 2025-02-13 The General Hospital Corporation Synthèses et utilisation de bloqueurs de canaux potassiques en imagerie tep et en thérapeutique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190094A1 (ar) * 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
CA3041650A1 (fr) * 2016-10-27 2018-05-03 Bayer Aktiengesellschaft 1,2,4-triazolones 4,5-annelees
JP7126556B2 (ja) * 2018-09-28 2022-08-26 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤

Also Published As

Publication number Publication date
CN113574054A (zh) 2021-10-29
PH12021551626A1 (en) 2022-05-02
WO2020144638A1 (fr) 2020-07-16
JP2022517086A (ja) 2022-03-04
US20220089568A1 (en) 2022-03-24
BR112021013134A2 (pt) 2021-09-28
KR20210114968A (ko) 2021-09-24
AU2020205842A1 (en) 2021-07-22
TW202043208A (zh) 2020-12-01
EP3908579A1 (fr) 2021-11-17
IL284537A (en) 2021-08-31
EP3908579B1 (fr) 2023-12-27
MX2021008400A (es) 2021-08-16
SG11202107276WA (en) 2021-07-29
CA3126330A1 (fr) 2020-07-16
ES2971680T3 (es) 2024-06-06

Similar Documents

Publication Publication Date Title
MA55716A (fr) Inhibiteurs de dihydroorotate déshydrogénase
EP4007752C0 (fr) Inhibiteurs de kif18a
EP4007753C0 (fr) Inhibiteurs de kif18a
DK3999506T3 (da) Parp1-hæmmere
IL292643A (en) Ras inhibitors
IL292644A (en) Ras inhibitors
IL292642A (en) Ras inhibitors
EP4007756C0 (fr) Inhibiteurs de kif18a
EP4262803A4 (fr) Inhibiteurs pan-kras de tétrahydropyridopyrimidine
MA54695A (fr) Inhibiteurs de dihydroorotate déshydrogénase
EP3843714C0 (fr) Inhibiteurs de cd73
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
DK3788040T3 (da) Pyridazinoner som parp7-inhibitorer
LT3980417T (lt) Prmt5 inhibitoriai
MA52413A (fr) Inhibiteurs de cd73
DK4051688T3 (da) Cd73-hæmmere
EP3761992A4 (fr) Inhibiteurs d'arginase
MA52812A (fr) Inhibiteurs de sarm1
EP3999517A4 (fr) Inhibiteurs de cd73
EP3980011A4 (fr) Inhibiteurs de sarm1
EP3787635A4 (fr) Inhibiteurs de cd73
MA52813A (fr) Inhibiteurs de sarm1
IL284989A (en) Dihydrourotate dehydrogenase inhibitors
EP4077282A4 (fr) Inhibiteurs de prmt5